Catecholamines and Cognition After Traumatic Brain Injury

Overview

Journal Brain

Publisher Oxford University Press

Specialty Neurology

Date 2016 Jun 4

PMID 27256296

Citations 47

Authors

Peter O Jenkins

Mitul A Mehta

David J Sharp

Affiliations

Soon will be listed here.

Abstract

Cognitive problems are one of the main causes of ongoing disability after traumatic brain injury. The heterogeneity of the injuries sustained and the variability of the resulting cognitive deficits makes treating these problems difficult. Identifying the underlying pathology allows a targeted treatment approach aimed at cognitive enhancement. For example, damage to neuromodulatory neurotransmitter systems is common after traumatic brain injury and is an important cause of cognitive impairment. Here, we discuss the evidence implicating disruption of the catecholamines (dopamine and noradrenaline) and review the efficacy of catecholaminergic drugs in treating post-traumatic brain injury cognitive impairments. The response to these therapies is often variable, a likely consequence of the heterogeneous patterns of injury as well as a non-linear relationship between catecholamine levels and cognitive functions. This individual variability means that measuring the structure and function of a person's catecholaminergic systems is likely to allow more refined therapy. Advanced structural and molecular imaging techniques offer the potential to identify disruption to the catecholaminergic systems and to provide a direct measure of catecholamine levels. In addition, measures of structural and functional connectivity can be used to identify common patterns of injury and to measure the functioning of brain 'networks' that are important for normal cognitive functioning. As the catecholamine systems modulate these cognitive networks, these measures could potentially be used to stratify treatment selection and monitor response to treatment in a more sophisticated manner.

Citing Articles

Antioxidant and Anti-Inflammatory Properties of Melatonin in Secondary Traumatic Brain Injury.

Sieminski M, Reimus M, Kalas M, Stepniewska E Antioxidants (Basel). 2025; 14(1).

PMID: 39857359 PMC: 11761219. DOI: 10.3390/antiox14010025.

Neuroscience of cancer: unraveling the complex interplay between the nervous system, the tumor and the tumor immune microenvironment.

Huang Q, Hu B, Zhang P, Yuan Y, Yue S, Chen X Mol Cancer. 2025; 24(1):24.

PMID: 39825376 PMC: 11740516. DOI: 10.1186/s12943-024-02219-0.

The Aggravating Role of Failing Neuropeptide Networks in the Development of Sporadic Alzheimer's Disease.

Jaszberenyi M, Thurzo B, Jayakumar A, Schally A Int J Mol Sci. 2024; 25(23).

PMID: 39684795 PMC: 11641508. DOI: 10.3390/ijms252313086.

Dysregulation of the dopaminergic system secondary to traumatic brain injury: implications for mood and anxiety disorders.

Mata-Bermudez A, Trejo-Chavez R, Martinez-Vargas M, Perez-Arredondo A, de Los Angeles Martinez-Cardenas M, Diaz-Ruiz A Front Neurosci. 2024; 18:1447688.

PMID: 39176379 PMC: 11338874. DOI: 10.3389/fnins.2024.1447688.

Changes in Noradrenergic Synthesis and Dopamine Beta-Hydroxylase Activity in Response to Oxidative Stress after Iron-induced Brain Injury.

Verduzco-Mendoza A, Mota-Rojas D, Olmos-Hernandez A, Avila-Luna A, Garcia-Garcia K, Galvez-Rosas A Neurochem Res. 2024; 49(11):3043-3059.

PMID: 39105899 DOI: 10.1007/s11064-024-04222-9.

References

Kellendonk C, Simpson E, Polan H, Malleret G, Vronskaya S, Winiger V . Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron. 2006; 49(4):603-15. DOI: 10.1016/j.neuron.2006.01.023. View

Whyte J, Hart T, Vaccaro M, Grieb-Neff P, Risser A, Polansky M . Effects of methylphenidate on attention deficits after traumatic brain injury: a multidimensional, randomized, controlled trial. Am J Phys Med Rehabil. 2004; 83(6):401-20. DOI: 10.1097/01.phm.0000128789.75375.d3. View

Arnsten A, Li B . Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol Psychiatry. 2005; 57(11):1377-84. DOI: 10.1016/j.biopsych.2004.08.019. View

Civelli O, Bunzow J, Grandy D, Zhou Q, Van Tol H . Molecular biology of the dopamine receptors. Eur J Pharmacol. 1991; 207(4):277-86. DOI: 10.1016/0922-4106(91)90001-x. View

Vijayraghavan S, Wang M, Birnbaum S, Williams G, Arnsten A . Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat Neurosci. 2007; 10(3):376-84. DOI: 10.1038/nn1846. View

Cools R, Lewis S, Clark L, Barker R, Robbins T . L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease. Neuropsychopharmacology. 2006; 32(1):180-9. DOI: 10.1038/sj.npp.1301153. View

Lieberman A, Goldstein M . Bromocriptine in Parkinson disease. Pharmacol Rev. 1985; 37(2):217-27. View

Fleckenstein A, Volz T, Riddle E, Gibb J, Hanson G . New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol. 2007; 47:681-98. DOI: 10.1146/annurev.pharmtox.47.120505.105140. View

Gibbs S, DEsposito M . Individual capacity differences predict working memory performance and prefrontal activity following dopamine receptor stimulation. Cogn Affect Behav Neurosci. 2005; 5(2):212-21. DOI: 10.3758/cabn.5.2.212. View

10.

Whitnall L, McMillan T, Murray G, Teasdale G . Disability in young people and adults after head injury: 5-7 year follow up of a prospective cohort study. J Neurol Neurosurg Psychiatry. 2006; 77(5):640-5. PMC: 2117429. DOI: 10.1136/jnnp.2005.078246. View

11.

Kelly C, de Zubicaray G, Di Martino A, Copland D, Reiss P, Klein D . L-dopa modulates functional connectivity in striatal cognitive and motor networks: a double-blind placebo-controlled study. J Neurosci. 2009; 29(22):7364-78. PMC: 2928147. DOI: 10.1523/JNEUROSCI.0810-09.2009. View

12.

Luciana M, Collins P . Dopaminergic modulation of working memory for spatial but not object cues in normal humans. J Cogn Neurosci. 2013; 9(3):330-47. DOI: 10.1162/jocn.1997.9.3.330. View

13.

Stevens M, Lovejoy D, Kim J, Oakes H, Kureshi I, Witt S . Multiple resting state network functional connectivity abnormalities in mild traumatic brain injury. Brain Imaging Behav. 2012; 6(2):293-318. DOI: 10.1007/s11682-012-9157-4. View

14.

Kim Y, Ko M, Na S, Park S, Kim K . Effects of single-dose methylphenidate on cognitive performance in patients with traumatic brain injury: a double-blind placebo-controlled study. Clin Rehabil. 2006; 20(1):24-30. DOI: 10.1191/0269215506cr927oa. View

15.

Bouret S, Sara S . Reward expectation, orientation of attention and locus coeruleus-medial frontal cortex interplay during learning. Eur J Neurosci. 2004; 20(3):791-802. DOI: 10.1111/j.1460-9568.2004.03526.x. View

16.

Fujinaka T, Kohmura E, Yuguchi T, Yoshimine T . The morphological and neurochemical effects of diffuse brain injury on rat central noradrenergic system. Neurol Res. 2003; 25(1):35-41. DOI: 10.1179/016164103101201094. View

17.

Mehta M, Swainson R, Ogilvie A, Sahakian J, Robbins T . Improved short-term spatial memory but impaired reversal learning following the dopamine D(2) agonist bromocriptine in human volunteers. Psychopharmacology (Berl). 2002; 159(1):10-20. DOI: 10.1007/s002130100851. View

18.

Nickels J, Schneider W, Dombovy M, Wong T . Clinical use of amantadine in brain injury rehabilitation. Brain Inj. 1994; 8(8):709-18. DOI: 10.3109/02699059409151025. View

19.

Failla M, Myrga J, Ricker J, Dixon C, Conley Y, Wagner A . Posttraumatic Brain Injury Cognitive Performance Is Moderated by Variation Within ANKK1 and DRD2 Genes. J Head Trauma Rehabil. 2015; 30(6):E54-66. PMC: 4626432. DOI: 10.1097/HTR.0000000000000118. View

20.

Kraus M, Smith G, Butters M, Donnell A, Dixon E, Yilong C . Effects of the dopaminergic agent and NMDA receptor antagonist amantadine on cognitive function, cerebral glucose metabolism and D2 receptor availability in chronic traumatic brain injury: a study using positron emission tomography (PET). Brain Inj. 2005; 19(7):471-9. DOI: 10.1080/02699050400025059. View